Roth Capital Partners Initiates Coverage on Cybin, With Buy Rating And USD$10 Price Target

April 28, 2021

Roth Capital Partners is initiating coverage of Cybin Inc. with a Buy rating and $10/share price target. Cybin develops alternative formulations and versions of existing psychedelic drugs.

Full Report (Link)

Roth Arrived at their 12-month price target of $10/share (USD) by assessing the after-tax, risk-adjusted NPV of potential future cash flows from the TRD indication and including a technology value for earlier programs. The probability-adjusted, fully taxed (21%) NPV (15% discount rate) of potential cash flows through 2035 is $2B or $9/share, in our calculation. Adding $200MM ($1/share) estimated technology value yields $2.2B or $10/share for the company, corresponding to our 12-month price target. Factors that could impede shares from reaching our price target include failure of Cybin’s drugs to demonstrate significant efficacy benefit or found to be unsafe, leading to the discontinuation of the programs.

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.